NCT04443829View on ClinicalTrials.gov

Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary CNS Lymphoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 23, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2032

Conditions
Primary CNS Lymphoma
Interventions
BIOLOGICAL

CD19CAR T-cells

Infusion with: CD19CAR T-cells

Trial Locations (1)

WC1E6BT

University College London Hospital, London

All Listed Sponsors
lead

University College, London

OTHER

NCT04443829 - Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary CNS Lymphoma | Biotech Hunter | Biotech Hunter